Spots Global Cancer Trial Database for On-demand PPI Therapy is Effective on Controlling Symptoms in Patients With Barrett's Esophagus.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: On-demand PPI Therapy is Effective on Controlling Symptoms in Patients With Barrett's Esophagus.

Official Title: The Impacts of On-demand Versus Continuous Esomeprazole Therapy on the Symptom Control and Histological Changes of Metaplastic Esophageal Epithelium in Patients With Barrett's Esophagus (EsoBE) - a Multicentre Randomized Controlled Trial

Study ID: NCT04329000

Conditions

Barrett Esophagus

Proton Pump Inhibitor

Symptom

Reflux

Interventions

Esomeprazole 40mg

Esomeprazole

Study Description

Brief Summary: On-demand PPI therapy is feasible for the long-term treatment of patients with Barrett's esophagus.

Detailed Description: Consecutive patients with symptomatic Barrett's esophagus are recruited and receive biopsy for esophageal metaplastic mucosa and gastric mucosa over the antrum and body during endoscopy on enrollment. The biopsy protocol for esophageal metaplastic mucosa is following Seattle protocol. GERD Q score will be conducted on enrollment. Additionally, blood sampling for CYP2C19 genotyping is also conducted on enrollment. The eligible subjects will be treated by 8-week esomeprazole, and are then randomly assigned to receive either maintenance or on-demand esomeprazole therapy (40 mg q.d.) for 40 weeks. The patients were asked to come back every four weeks for the recording of symptom days and PPI tablet consumption numbers. Follow-up endoscopy with biopsy for esophageal and gastric mucosa is performed at the end of the 48th weeks. We will compare the effects of maintenance and on-demand PPI therapy on (1) histological changes of esophageal metaplastic mucosa (2) symptom control (3) tablet consumption number